Table 1.
Baseline patient characteristics and pharmacological treatments according to sex
| All | Men | Women | P-value | |
|---|---|---|---|---|
| Patients | 96 (100%) | 74 (77%) | 22 (33%) | – |
| Age (years) | 72.4±5.4 | 72.2±5.7 | 72.9±4.0 | 0.757 |
| Smokers | 48 (50%) | 37 (50%) | 11 (50%) | 1.000 |
| Inhalation therapy | 43 (44.8%) | 36 (48.6%) | 7 (31.8%) | 0.166 |
| Antibiotics | 24 (25%) | 19 (25.7%) | 5 (22.7%) | 0.780 |
| ACE-I | 42 (43.8%) | 32 (43.2%) | 10 (45.5%) | 0.855 |
| ARBs | 21 (21.9%) | 16 (21.6%) | 5 (22.7%) | 0.913 |
| β-blockers | 18 (18.8%) | 14 (18.9%) | 4 (18.2%) | 0.938 |
| Oxygen | 64 (66.7%) | 48 (64.9%) | 16 (72.7%) | 0.494 |
| Calcium channel blocker | 27 (28.1%) | 21 (28.4%) | 6 (27.3%) | 0.920 |
| Aspirin | 30 (31.3%) | 20 (27%) | 10 (45.5%) | 0.103 |
Notes: Data are expressed as means ± standard deviations or frequencies and percentages for continuous and categorical variables, respectively. The P-value was estimated by the chi-square test and the two-sample t-test for categorical and continuous variables, respectively.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.